전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
tsütogeneetilised kõrvalekalded
cytogenetic abnormalities
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
kolmel patsiendil esinesid enne ravi tsütogeneetilised kõrvalekalded.
three patients had cytogenetic abnormalities at baseline.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
tsütogeneetilised analüüsid esmakordselt ravi saavatel b- kll- iga patsientidel:
27 cytogenetic analyses in first line b-cll patients:
마지막 업데이트: 2012-04-11
사용 빈도: 4
품질:
tsütogeneetilised analüüsid esimese rea ravi saavatel b-kll-iga patsientidel:
cytogenetic analyses in first line b-cll patients:
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
tsütogeneetilised vastused põhinesid ph+ metafaaside protsendil (≥ 20 metafaasis rakust) igas luuüdi proovis.
cytogenetic responses were based on the percentage of ph+ metaphases among >/= 20 metaphase cells in each bone marrow sample.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
uuringupatsientide vanuse mediaanväärtus oli 57 aastat, neist 55% olid meessoost ja 48% patsientidest olid kõrgriski tsütogeneetilised markerid.
median age of the patients in the study was 57 years, 55% were male and 48% of patients had high-risk cytogenetics.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
osana uuringusse kaasamise kriteeriumitest pidi patsientide sooritusvõime olema 0–2 ecog määratluse alusel ning tsütogeneetilised muutused pidid vastama keskmisele või kõrgele riskiastmele.
as part of the inclusion criteria, patients were required to have an ecog performance status of 0-2 and intermediate- or poor-risk cytogenetic abnormalities.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Üksteist patsienti saavutasid kiire täieliku hematoloogilise ravivastuse; kümnel kadusid täielikult tsütogeneetilised kahjustused ja kadusid või vähenesid liittranskriptid rt - pcr mõõtmisel.
eleven patients achieved rapid chr; ten had complete resolution of cytogenetic abnormalities and a decrease
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
ligikaudu 12% patsientidest, kelle tsütogeneetilised näitajad olid uuringu alustamisel normaalsed, täheldati rutiinsel korduval hindamisel rakulisi muutusi, sh monosoomiat 7.
a subset of approximately 12% of patients who had normal cytogenetic evaluations at baseline was subsequently found to have abnormalities, including monosomy 7, on routine repeat evaluation.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
filgrastiimi ei tohi manustada raske kaasasündinud neutropeeniaga (kostmanni sündroom) patsientidele, kellel esinevad tsütogeneetilised kõrvalekalded (vt allpool).
filgrastim should not be administered to patients with severe congenital neutropenia (kostman's syndrome) with abnormal cytogenetics (see below).
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
filgrastiimi ohutus ja efektiivsus ei ole tõestatud alla 55-aastastel de novo ägeda müeloidse leukeemiaga patsientidel, kellel on head tsütogeneetilised näitajad [t (8; 21), t (15; 17) ja inv (16)].
the safety and efficacy of filgrastim administration in de novo aml patients aged < 55 years with good cytogenetics [t (8; 21), t (15; 17), and inv (16)] have not been established.
마지막 업데이트: 2017-04-26
사용 빈도: 4
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다